-α , RANTES, substance P, and hydrogen sulfide in acute pancreatitis and the resultant MODS. This review intends to present an overview of the inflammatory response that takes place following pancreatic acinar cell injury.
INTRODUCTION
Acute pancreatitis is an inflammatory disorder, and inflammation not only affects the pathogenesis but also the course of the disease. At present it is widely accepted that the premature activation of digestive enzymes within the pancreatic acinar cells is a critical initiating event that leads to auto-digestion of pancreas (1-3). Acinar cell injury leads to a local inflammatory reaction. Indeed, there is evidence to show that the acinar cell itself produces inflammatory mediators, such as chemokines (1-3, 4). If this inflammatory reaction is very strong, it leads to a systemic inflammatory response syndrome (SIRS), and it is this systemic response that is ultimately responsible for the majority of the morbidity and mortality (1-3). Systemic leukocyte activation is a direct consequence of a SIRS and if excessive, it can lead to distant organ damage and multiple organ dysfunction syndrome (MODS) (1-3).
An important characteristic feature of acute pancreatitis is the pancreatic inflammation with excessive recruitment of leukocytes. Inflammatory mediators appear to play a critical role in the pathogenesis of pancreatitis and more so of the subsequent inflammatory response (1-3). Inflammatory mediators believed to participate in the pathophysiology of this condition include: tumor necrosis factor-α (TNF-α ), interleukin-1 (IL-1β ), interleukin-6 (IL-6), platelet activating factor (PAF), intercellular adhesion molecule-1 (ICAM-1), interleukin-8 (IL-8), growth related oncogene-a/cytokine-induced neutrophil chemoattractant (GRO-α /CINC), monocyte chemoattractant protein-1 (MCP-1), interleukin 10 (IL-10), complement component C5a, substance P, hydrogen sulfide (H 2 S), and neutral endopeptidase (NEP) (1-3) (Table 1).
TNF-α AND IL-1β
Tumor necrosis factor-α (TNF-α ) and interleukin-1β (IL-1β ) are derived predominantly from activated macrophages and act via specific cell membrane bound receptors. Levels of both these pro-inflammatory mediators are elevated upon the onset and during the progress of acute pancreatitis (5, 6). Naturally occurring soluble TNF receptors (sTNFR) and interleukin-1 receptor antagonist (IL-1ra), by neutralizing the activity of TNF-α and IL-1β respectively, act as anti-inflammatory mediators (5, 6). Intrapancreatic TNF-α and IL-1β are detectable one hour following induction of acute pancreatitis and levels increase rapidly over the following six hours (5, 6). Both TNFα and IL-1β are thought to play an important role in acute pancreatitis.
Combined infusions of TNF-α and IL-1β have synergistic pro-inflammatory effects (5, 6). Using knockout mice deficient in IL-1 type 1 receptors, TNF type 1 receptors, or both, it has been shown that IL-1β and TNF-α make an equivalent contribution to the severity of an attack. Preventing the activity of both cytokines concurrently has no additional effect on the degree of pancreatitis but does attenuate the systemic stress response and is associated with an additional but modest decrease in mortality (7). Numerous investigators have employed specific antagonists to TNF-α or IL-1β in experimental models of acute pancreatitis. Examples of this approach include the use of an anti-TNF-α antibody, soluble type 1 TNF receptor and IL-1ra (7, 8). Blockade of the IL-1 receptor before or soon after induction of pancreatitis is associated with decreased severity of pancreatitis and reduced intrinsic pancreatic damage. Also, neutrali-zation of TNF-α with a polyclonal antibody significantly reduces the severity of acute pancreatitis in the rats (8).
IL-6
Interleukin 6 (IL-6) is produced by a wide range of cells including monocytes/macrophages, endothelial cells, fibroblasts and smooth muscle cells in response to stimulation by endotoxin, IL-1β and TNFα (1-3). IL-6 levels are raised in patients with acute pancreatitis and correlate with disease severity (9). Transgenic mice overexpressing IL-6 are more susceptible to acute pancreatitis, and in these mice a monoclonal anti-IL-6 antibody has a protective effect (10) .
IL-10
Interleukin-10 (IL-10) is an anti-inflammatory cytokine. Its plasma levels are elevated in animal models of endotoxemia and inhibit the release of pro-inflammatory cytokines (i.e. IL-1β , IL-6 and TNF-α ) from monocytes/macrophages thus preventing subsequent tissue damage. IL-10 also stimulates production of the naturally occurring IL-1 receptor antagonist (IL-1ra) and release of the soluble p75 TNF receptor (11) . IL-10 is believed to have a protective role in acute pancreatitis. In normal subjects IL-10 is not measurable in serum, but in acute pancreatitis levels are markedly raised within the first 24 hours of an attack followed by a steady decline over the following few days Administration of IL-10 in experimental acute pancreatitis reduces the local inflammatory response and subsequent mortality (12) . In a study, prophylactic administration of IL-10 to patients undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) reduced the incidence of pancreatitis (pain and hyperamylasemia) from 24.4 % to 6.8 %. Only two patients had severe acute pancreatitis, i.e. developed organ failure or had an in patient stay greater than ten days. Therefore it is at present uncertain if IL-10 will reduce the severity of acute pancreatitis in patients with severe disease from other causes (13) .
PAF
Platelet activating factor (PAF) is a low molecular weight phospholipid which acts via specific cell surface receptors that have been identified on numerous cells and tissues including platelets, leukocytes and endothelial cells (1-3). Isolated pancreatic acini have been reported to synthesize PAF and pancreatic tissue concentrations rise during the course of an attack. In animal models intra-peritoneal or intravascular injection can bring about or increase the severity of acute pancreatitis (14) . Blood and pulmonary tissue levels also rise co-ordinately indicating that PAF is a key mediator of the systemic inflammatory response (14) . Specific PAF antagonists have been evaluated in experimental models with varying success. Prophylactic treatment with these antagonists causes a reduction in local inflammation and acinar cell necrosis, in several experimental models of acute pancreatitis (15, 16) . In a recent study using a model of severe acute pancreatitis induced by infusion of bile salts into the pancreatic duct in combination with caerulein administered intravascularly, treatment with lexipafant, a PAF antagonist had no effect on survival or local inflammation (16) .
PAF is inactivated by the enzyme platelet activating factor acetylhydrolase (PAF-AH). In severe acute pancreatitis induced by the ligation of combined biliopancreatic duct in the opossum, there was significant protection against acute pancreatitis and associated lung injury by treatment with PAF-AH (17) .
Despite promising results from a phase II clinical study, in a large multicenter phase III study lexipafant failed to reduce organ failure or mortality in severe acute pancreatitis (18) . Further development of lexipafant as a therapy for acute pancreatitis has since been abandoned (19) . It is noteworthy that some experimental studies had also shown lack of effect of lexipafant. Nevertheless, large multicenter studies such as these demonstrate that it is possible to investigate the potential of anti-inflammatory mediator therapy in the clinic.
CD40L
CD40, a member of the tumor necrosis factor (TNF) receptor family, is expressed on the membrane of a variety of cells, including B lymphocytes, monocytes, dendritic cells, and biliary epithelial cells. CD40 binds to its ligand CD40L (also referred to as CD154) to mediate major immunoregulatory signals. Although CD40L expression was previously thought to be restricted to activated T lymphocytes, this cell surface protein has been detected in various cell types, including macrophages, smooth muscle and endothelial cells. In pancreatic tissue from control mice and caerulein-treated mice, the expression of both CD40 and CD40L was detected on the acinar cell surface. Interestingly, pancreatitis and pancreatitis-associated lung injury were markedly decreased in mice deficient in CD40L compared with wild-type mice, suggesting an important pro-inflammatory role of CD40L in the pathogenesis of acute pancreatitis and associated lung injury (20) .
ICAM-1
Intercellular adhesion molecule-1 (ICAM-1; CD54) is an inducible protein expressed on the surface of endothelial cells. Under physiological conditions, ICAM-1 is not constitutively expressed or is expressed at low levels in most tissues; during inflammation its levels are upregulated (1-3). It has recently been reported that ICAM-1 is present on rat pancreatic acinar cells, is upregulated by caerulein and mediates direct binding of neutrophils to acinar cells (21) . ICAM-1 was also upregulated in pancreas of rats with experimental pancreatitis induced by supramaximal doses of caerulein (21) . ICAM-1 knockout mice are protected against acute pancreatitis and associated lung injury, pointing to an important role for ICAM-1 in the development of pancreatitis and subsequent organ damage (22) . The protective effect of ICAM-1 gene deletion does not differ from that seen following neutrophil depletion in the cholinedeficient, ethionine supplemented (CDE) diet model of acute pancreatitis (23) . Indeed neutrophil depletion in ICAM-1 knockout mice affords no additional protection (22) . Blocking ICAM-1 has been shown to have a protective effect against local and systemic organ damage in different experimental models of acute pancreatitis (24) . These results suggest that ICAM-1 deficiency interferes with neutrophil recruitment and supports the concept of a therapeutic strategy directed against neutrophil migration and activation.
C5a
C5a is a potent anaphylatoxin and chemoattractant that is generated from C5 as part of both the classic and alternate pathways of complement activation. C5a, acting via C5aR on target cells, is generally believed to serve as a "complete" proinflammatory mediator. We evaluated the role of C5a in a model of pancreatitis and systemic injury after pancreatitis using two independent but complementary approaches. In the first, mice that do not express C5aR were used, whereas in the second set of experiments, mice that do not express C5 were employed. The results of both studies were similar, i.e., interruption of C5a action either by deletion of its receptor or by deletion of its parent protein resulted in a worsening of pancreatitis. The severity of pancreatitis-associated lung injury was also increased when C5a action was rendered inoperative (25) .
CHEMOKINES
Leukocyte chemotaxis in acute pancreatitis is a well orchestrated process that involves a number of proteins, including pro-inflammatory cytokines, adhesion molecules, matrix metalloproteinases and the large cytokine subfamily of chemotactic cytokinesthe chemokines (1-3). Numerous chemokines have now been identified as inflammatory mediators with potent leukocyte activating properties and many of them have been shown to be involved in the pathophysiological process of experimental acute pancreatitis.
Chemokines have been divided into four major sub-groups: C, CC, CXC and CX 3 C, on the basis of the position and spacing of N-terminal cysteine residues (1-3). Historically, CC chemokines (such as MCP-1, MIP-1α , RANTES) have been believed to act principally upon monocytes, and CXC chemokines which contain a three amino acid ELR motif at the amino terminal end (such as IL-8, GRO-α , ENA-78) are believed to act upon neutrophils. Recent work by us, as well as other investigators, has, however, shown that these narrow definitions are no longer valid (26) (27) (28) .
Mob1, a CXC rat chemokine, was shown to be elevated within one hour of induction of acute pancreatitis in the rat by caerulein hyperstimulation (29) . We have recently shown that pancreatic acinar cells produce the CC chemokine MCP-1 and that treatment with supramaximally stimulating doses of caerulein causes an upregulation of MCP-1 production. Caerulein-induced stimulation of chemokine production is regulated via NF-κ B and Ca 2+ (4).
Levels of IL-8, GRO-α , and ENA-78 (epithelial-derived neutrophil-activating peptide 78) are raised in clinical acute pancreatitis and are predictors of disease severity (30, 31) . The chemokines are an ideal target for anti-inflammatory therapy.
The best characterized of the rat CXC chemokines is CINC (cytokine-induced neutrophil chemoattractant), the homologue of the human chemokine GROα (growth related oncogene-α ). Circulating levels of CINC are raised in experimental acute pancreatitis (32) and treatment with neutralizing antibody against CINC protects rats against acute pancreatitis-associated lung injury (33) . We have also shown that in knockout mice, the deletion of the MIP-1α /RANTES receptor CCR1 decreased the pulmonary damage seen in severe acute pancreatitis. There was little protection against pancreatic damage (26) . Similarly, treatment with Met-RANTES, a CCR1 antagonist, protected mice against acute pancreatitis-associated lung injury, with little protection against pancreatic damage (28) . These studies show the critical role of chemokines in the pathogenesis of acute pancreatitis and associated lung injury.
SUBSTANCE P AND NEUTRAL ENDOPEPTIDASE
Substance P is an 11 amino acid neuropeptide that is released from nerve endings in many tissues. Subsequent to its release, substance P binds to neurokinin-1 (NK1) receptors on the surface of effector cells and in addition to being a mediator of pain it has been shown to play an important role in inflammation. We have earlier shown the presence of substance P in the pancreas and of NK1 receptors on pancreatic acinar cells in mice (34) . On induction of pancreatitis, there is a several fold upregulation of pancreatic substance P levels and of NK1 receptors on pancreatic acinar cells (34) . Moreover, knockout mice deficient in NK1 receptors are protected against pancreatitis. Interestingly, these mice are almost completely protected against pancreatitis-associated lung injury (34) . In a recent paper, we have shown for the role of preprotachykinin-A (PPT-A) gene products (e.g. substance P and neurokinin-A) in the pathogenesis of acute pancreatitis and associated lung injury (35) . NK1 receptors bind other peptides in addition to substance P, not all of which are derived from the PPT-A gene. In this study, we found that knockout mice deficient in the PPT-A gene were protected against acute pancreatitis and associated lung injury (35) . Furthermore, both prophylactic, and therapeutic, treatment with CP-96345, an antagonist of the NK1 receptor, protected mice against acute pancreatitis and associated lung injury (36) . These three papers clearly show that PPT-A gene products, acting via NK1 receptors, are critical pro-inflammatory mediators in acute pancreatitis and the associated lung injury. These results are further substantiated by the observation that knockout mice deficient in neutral endopeptidase (NEP), the enzyme that hydrolyses substance P thereby terminating its action, are more susceptible to experimental acute pancreatitis and associated lung injury (37, 38) .
These results demonstrate the critical role played by substance P in the pathogenesis of acute pancreatitis and point to a potential therapeutic approach against this clinical condition.
The toxic effect of H 2 S on living organisms has been recognized for nearly three hundred years. However, growing evidence has accumulated in recent years which suggests that H 2 S is formed naturally in mam-malian tissues and exhibits a range of biological and physiological functions. Cystathionine-γ -lyase (CSE), which utilizes L-cysteine as substrate, is the enzyme responsible for the production of H 2 S in mammalian vascular tissues. In a recent paper, we have shown the presence of H 2 S synthesizing enzyme activity and CSE (as determined by mRNA signal) in the pancreas. Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury (39) . This study has shown H 2 S as a novel inflammatory mediator that plays a key role in acute pancreatitis and associated lung injury CONCLUSIONS Significant progress has been made in recent years in our awareness on the role of inflammatory responses in the pathogenesis of acute pancreatitis (Fig. 1) . In most of the studies, experimental animal models were used, while early clinical studies show clinical relevance of these findings. An understanding of the elucidation of the key mediators of inflammation in acute pancreatitis and associated MODS coupled with the discovery of specific inhibitors is likely to make it possible to develop clinically effective anti-inflammatory therapy. 
